

# Stock Sentiment Analysis Report

Revvity (RVTY)

Analysis Period: 2026-03-06 to 2026-04-05 (30 days)

Generated: 2026-04-05 09:23:53

## Executive Summary


Sentiment analysis for Revvity (RVTY) from 2026-03-06 to 2026-04-05. Analyzed 18 items across FDA and news sources.

## Sentiment Breakdown

Category	Count	Percentage
Positive	8	44.4%
Negative	5	27.8%
Neutral	5	27.8%
<b>Total</b>	<b>18</b>	<b>100.0%</b>

**Overall Sentiment: NEUTRAL**

## Sentiment Trend Over Time



## Key Findings

No key findings available.

## Top Positive Events

Title	Source	Date	Score
Nephron Research gets more bullish on Revvity, upg...	news	2026-03-26	0.991
[Latest] Global Environmental Mass Spectrometry Ma...	news	2026-04-02	0.859
COVID-19 Tests Market Report 2025: Segments, Share...	news	2026-03-12	0.859
Catabolism of extracellular glutathione supplies c...	news	2026-03-18	0.856
A structure-based mRNA vaccine for Nipah virus in ...	news	2026-03-12	0.852

## Top Negative Events

Title	Source	Date	Score
The E3 ubiquitin ligase mechanism specifying targe...	news	2026-03-18	-0.778
Ectopic NMDAR expression in cancer unmasks germlin...	news	2026-03-25	-0.660
Epigenetics Market to Surpass US \$35.84 Billion by...	news	2026-03-11	-0.660
A $\mu$ -opioid receptor superagonist analgesic with mi...	news	2026-04-01	-0.612
Is Revvity Stock Underperforming the S&P; 500?	news	2026-03-20	-0.200